)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Atrys Health
Atrys Health (ATRY) investor relations material
Atrys Health Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary10 Sep, 2026
Executive summary
H1 2026 revenue reached €77.734m, up 9.4% YoY, while EBITDA increased 21.3% to €9.3m; revenue growth accelerated to 12.3% in Q2.
Consolidated net loss narrowed to €6.426m from €9.406m; operating loss improved to €1.312m from €3.133m.
Growth was driven by Oncology, Nuclear Medicine and international operations, particularly Latin America; FY 2026 guidance was reaffirmed.
The January 2026 €145m Prevention Division sale supported deleveraging, reducing net financial debt to €35.4m.
Financial highlights
Gross profit rose 6.6% to €32.7m; gross margin declined to 42.0% from 43.1% due to business mix.
Reported operating cash flow rose 191.5% to €7.2m, with H1 investments of €2.1m; cash-flow-statement operating cash flow was negative €0.063m versus positive €3.108m.
Financial result improved to a €5.165m loss from a €10.374m loss; financial expenses fell €4.4m YoY.
Excluding accounting effects, EBITDA growth exceeded 44%.
Outlook and guidance
FY 2026 guidance reaffirmed: revenue €156.5m (+11%), reported EBITDA €20.5m (+40%) and operating cash flow €13.5m (+125%).
Debt restructuring is underway to align financing with the 2026–2028 Strategic Plan.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Atrys Health
- Revenue and adjusted EBITDA grew, but financing costs and impairments deepened the net loss.ATRY
H2 2023 - H1 revenue and adjusted EBITDA grew, and FY2024 guidance was reaffirmed.ATRYQ2 2024
- Revenue and EBITDA grew as the ASPY sale cut net debt 81.1%.ATRYQ1 2026
- Revenue rose 8.5%, while the ASPY sale cut net debt amid a €100,547k net loss.ATRYQ4 2025
- 8.2% revenue growth driven by Oncology and Diagnostics; ASPY divestment to cut debt and refocus.ATRYQ3 2025
- Revenue rose 7.8%, while adjusted EBITDA fell 13.3% as the net loss narrowed.ATRYQ2 2025
- 9M revenue rose 5.8%, adjusted EBITDA 31.7%, and operating cash flow 60.8%.ATRYQ3 2024
- Q1 revenue rose 11.2%; Marian Isach is set to become CEO in June.ATRYQ1 2025
- Revenue and adjusted EBITDA grew as losses narrowed and leverage improved.ATRYQ4 2024
Next Atrys Health earnings date
Q3 202616 Nov, 2026
Atrys Health
Next Atrys Health earnings date
Q3 202616 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Atrys Health S.A. provides medical diagnostics and precision medicine services. Its business includes radiology, oncology, and genetic testing for hospitals and healthcare providers, with operations across Spain and Latin America. The company is headquartered in Madrid, Spain, and its shares are listed on the BME Growth.